Holen Sie sich die Stockscreener-App
0.69
20.42%
0.117
Handel nachbörslich:
.69
Schlusskurs vom Vortag:
$0.573
Offen:
$0.58
24-Stunden-Volumen:
4.28M
Relative Volume:
5.65
Marktkapitalisierung:
$27.34M
Einnahmen:
$1.04M
Nettoeinkommen (Verlust:
$-67.50M
KGV:
-0.359
EPS:
-1.9222
Netto-Cashflow:
$-60.67M
1W Leistung:
+28.30%
1M Leistung:
+10.42%
6M Leistung:
-84.17%
1J Leistung:
-70.76%
1-Tages-Spanne:
$0.5347
$0.7099
1-Wochen-Bereich:
$0.52
$0.7099
52-Wochen-Spanne:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.69 | 22.70M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2025-12-17 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-17 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
VistaGen Therapeutics (VTGN) Q4 2026 earnings summary - Quartr
VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative
vtgn-20260331 - SEC.gov
VTGN: Net loss increased to $69.7M as R&D spending rose, with cash reserves at $45.4M and going concern risk - TradingView
Vistagen Reports FY2026 Net Loss $69.7M; Cash and Marketable Securities $45.4M - TradingView
VTGN: Advanced clinical milestones and maintained cash runway despite increased net loss - TradingView
Vistagen (NASDAQ: VTGN) advances fasedienol trials as FY 2026 loss deepens - Stock Titan
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Business Wire
Generalized Anxiety Disorder Market: Growth Momentum Across 7MM to 2036 – DelveInsight | VistaGen Therapeutics, Fabre-Kramer Pharm, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Lab - Barchart.com
VTGN Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Edges HigherGuidance vs Actual - newsline.com
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics (VTGN) Edges Higher Amid Cautious TradingRVOL Breakout - newsline.com
Vistagen (VTGN) Achieves Key Milestone in Social Anxiety Disorder Treatment - GuruFocus
Vistagen achieves ICH E1 safety exposure milestones for fasedienol; >1,500 subjects exposed - TradingView
Vistagen (VTGN) reaches ICH safety exposure goal in Phase 3 fasedienol program - Stock Titan
Vistagen meets ICH E1 safety exposure targets for fasedienol By Investing.com - Investing.com Australia
Nasal spray for social anxiety clears key safety bar in 1,500 people - Stock Titan
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - GuruFocus
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching - Bez Kabli
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineEPS Revision Trend - The Legal Advocate
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Ami - GuruFocus
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Amid Key Trial Updates - GuruFocus
Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC - Stock Titan
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference - Yahoo Finance
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Vistagen Therapeutics (VTGN) Holds Near Support After Minor DeclineBullish Sentiment - The Legal Advocate
Vistagen Therapeutics (VTGN) Shows Modest Gain Amid Tight Trading RangeWave Equality - The Legal Advocate
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Stock Price, Quote & Chart | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss as Vistagen Advances Pipeline, Stock Edges LowerSubscription Growth Report - The Legal Advocate
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
Vistagen Therapeutics (VTGN) Stock: Up +0.98%, Key Resistance at $0.67 2026-05-20Bull Flag - The Legal Advocate
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
[SCHEDULE 13G/A] Vistagen Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
All News about Vistagen Therapeutics, Inc.Common Stock - The Chronicle-Journal
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Inside Vistagen: CEO joins RBC healthcare fireside chat on May 20 - Stock Titan
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - marketscreener.com
Vistagen Therapeutics, Inc.Common Stock (NQ: VTGN - FinancialContent
Vistagen Reports Positive 12-Month Data for Fasedienol Nasal Spray in Social Anxiety Disorder Phase 3 Trial - Minichart
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):